Clinical Trials
17 trialsNCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT06012435 2026-05-27
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Seagen Inc.
Phase 3 Active not recruiting
NCT06780098 2026-05-26
MK-3475-01I
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05800587 2026-05-22
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT05096663 2026-05-18
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2/3 Active not recruiting
NCT03611738 2026-05-15
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT04310007 2026-05-13
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06632327 2026-05-08
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06616584 2026-05-05
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2/3 Recruiting
NCT06635824 2026-05-05
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Genmab
Phase 3 Active not recruiting
NCT02664935 2026-04-28
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Completed
NCT05132075 2026-04-21
KontRASt-02
Novartis
Phase 3 Active not recruiting
NCT06623656 2026-04-21
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT05450692 2026-04-16
LATIFY
AstraZeneca
Phase 3 Active not recruiting
NCT01630733 2026-04-15
ENSPIRIT
Achieve Life Sciences
Phase 3 Completed
NCT05633667 2026-03-17
VELOCITY-Lung
Gilead Sciences
Phase 2 Recruiting
NCT06881784 2026-03-12
RASolve 301
Revolution Medicines, Inc.
Phase 3 Recruiting